HU-331

Description

The endocannabinoids present a rich system of central cannabinoid (CB₁), peripheral cannabinoid (CB₂), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation.HU-331 synthesis,hu-331 standard,hu-210,hu-320,Quinone

HU-331 is a hydroxylquinone cannabidiol analog that exhibits potent antineoplastic activity on a variety of human cancer cell lines.

It effectively inhibits the growth of human Raji and Jurkat lymphoma cells in vitro with an EC₅₀ of approximately 0.2 µg/ml and an EC₈₀ of 1.56 µg/ml. HU-331 also inhibits the growth of HT-29 colon carcinoma cells, which have been inoculated into nude mice, by more than 50% at a dose of 5 mg/kg.

HU-331 is a quinone anticarcinogenic drug synthesized from cannabidiol, a cannabinoid in the Cannabis sativa plant.

It showed a great efficacy against oncogenic human cells. It does not cause arrest in cell cycle, cell apoptosis or caspase activation.

HU-331 inhibits DNA topoisomerase II even at nanomolar concentrations, but has shown a negligible effect on the action of DNA topoisomerase I. AM 2201

The cannabinoid quinone It is a very specific inhibitor of topoisomerase II, compared with most known anticancer quinones.

One of the main objectives of these studies is the development of a new quinone derived compound that produces anti-neoplastic activity while maintaining low toxicity at therapeutic doses.